Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulseless electrical activity02.03.04.0200.000112%Not Available
Skin oedema23.06.04.0010.000168%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000862%Not Available
Angiopathy24.03.02.007--Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000168%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.0270.002485%
Neurological symptom17.02.05.0100.000448%Not Available
Aortic rupture24.03.04.009; 12.01.11.007--Not Available
Appetite disorder14.03.01.004; 19.09.01.002--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Ocular toxicity12.03.01.031; 06.11.01.0060.000280%Not Available
Embolism24.01.01.009--
Haematotoxicity12.03.01.025; 01.05.01.0070.000918%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.089--Not Available
Limb discomfort15.03.04.0140.000839%Not Available
Intra-abdominal haemorrhage24.07.02.035; 07.12.02.008; 12.01.17.0110.000112%
Ischaemic stroke24.04.06.010; 17.08.01.0180.001063%Not Available
Jaw disorder15.02.04.0090.000358%Not Available
Joint lock15.01.08.0040.000224%Not Available
Laryngeal disorder22.04.01.0010.000112%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Metastatic neoplasm16.16.01.0070.000224%Not Available
Motor dysfunction15.05.06.006; 17.01.02.0310.000246%Not Available
Neoplasm progression16.16.02.005--Not Available
Partial seizures17.12.03.0100.000112%Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene